Results from the global phase III IMforte trial found that maintenance therapy with a combination of the alkylating agent lurbinectedin and the PD-L1 inhibitor atezolizumab improved survival in some p...
A rare case of pneumomediastinum and subcutaneous emphysema following dental cleaning requires high-flow oxygen therapy rather than invasive interventions. Learn why.
Health care facilities face new challenges as sensitive locations policy protecting them from immigration enforcement was rescinded in January 2025, requiring new protocols for patient protection.
Phase III trial results show that once-daily brensocatib reduces pulmonary exacerbations and slows lung function decline in patients with bronchiectasis.